University of Alberta. Islet isolation using MnTE-2-PyP (BMX-010). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02457858. NLM Identifier: NCT02457858, Accessed on August5, 2014.
2.
AliDK, OriowoM, TovmasyanA, Batinic-HaberleI, and BenovL. Late administration of Mn porphyrin-based SOD mimic enhances diabetic complications. Redox Biol, 1: 457–466, 2013.
3.
AshcraftKA, BossMK, TovmasyanA, Roy ChoudhuryK, FontanellaAN, YoungKH, PalmerGM, BirerSR, LandonCD, ParkW, DasSK, WeitnerT, ShengH, WarnerDS, BrizelDM, SpasojevicI, Batinic-HaberleI, and DewhirstMW. Novel manganese-porphyrin superoxide dismutase-mimetic widens the therapeutic margin in a preclinical head and neck cancer model. Int J Radiat Oncol Biol Phys, 93: 892–900, 2015.
4.
AstonK, RathN, NaikA, SlomczynskaU, SchallOF, and RileyDP. Computer-aided design (CAD) of Mn(II) complexes: superoxide dismutase mimetics with catalytic activity exceeding the native enzyme. Inorg Chem, 40: 1779–1789, 2001.
5.
BarneseK, GrallaEB, CabelliDE, and ValentineJS. Manganous phosphate acts as a superoxide dismutase. J Am Chem Soc, 130: 4604–4606, 2008.
6.
Batinic-HaberleI, BenovL, SpasojevicI, and FridovichI. The ortho effect makes manganese(III) meso-tetrakis(N-methylpyridinium-2-yl)porphyrin a powerful and potentially useful superoxide dismutase mimic. J Biol Chem, 273: 24521–24528, 1998.
7.
Batinic-HaberleI, CuzzocreaS, ReboucasJS, Ferrer-SuetaG, MazzonE, Di PaolaR, RadiR, SpasojevicI, BenovL, and SalveminiD. Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med, 46: 192–201, 2009.
8.
Batinic-HaberleI, RajicZ, TovmasyanA, ReboucasJS, YeX, LeongKW, DewhirstMW, VujaskovicZ, BenovL, and SpasojevicI. Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med, 51: 1035–1053, 2011.
9.
Batinic-HaberleI, ReboucasJS, and SpasojevicI. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal, 13: 877–918, 2010.
10.
Batinic-HaberleI, and SpasojevicI. Complex chemistry and biology of redox-active compounds, commonly known as SOD mimics, affect their therapeutic effects. Antioxid Redox Signal, 20: 2323–2325, 2014.
11.
Batinić-HaberleI, SpasojevićI, HambrightP, BenovL, CrumblissAL, and FridovichI. Relationship among redox potentials, proton dissociation constants of pyrrolic nitrogens, and in vivo and in vitro superoxide dismutating activities of manganese(III) and iron(III) water-soluble porphyrins. Inorg Chem, 38: 4011–4022, 1999.
12.
Batinic-HaberleI, TovmasyanA, RobertsER, VujaskovicZ, LeongKW, and SpasojevicI. SOD Therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal, 20: 2372–2415, 2014.
13.
Batinic-HaberleI, TovmasyanA, and SpasojevicI. An educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins—from superoxide dismutation to H2O2-driven pathways. Redox Biol, 5: 43–65, 2015.
14.
Batinic HaberleI, TovmasyanA, and SpasojevicI. The complex mechanistic aspects of redox-active compounds, commonly regarded as SOD mimics. BioInorg React Mech, 9: 35–58, 2013.
CelicT, SpanjolJ, BobinacM, TovmasyanA, VukelicI, ReboucasJS, Batinic-HaberleI, and BobinacD. Mn porphyrin-based SOD mimic, MnTnHex-2-PyP(5+), and non-SOD mimic, MnTBAP(3-), suppressed rat spinal cord ischemia/reperfusion injury via NF-kappaB pathways. Free Radic Res, 48: 1426–1442, 2014.
17.
ChaiswingL, ZhongW, and OberleyTD. Distinct redox profiles of selected human prostate carcinoma cell lines: implications for rational design of redox therapy. Cancers (Basel), 3: 3557–3584, 2011.
18.
ChenQ, EspeyMG, SunAY, PooputC, KirkKL, KrishnaMC, KhoshDB, DriskoJ, and LevineM. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A, 105: 11105–11109, 2008.
19.
CourtneyRC, ChaberekS, and MartellAE. Stability of metal chelates. VII. N,N′-Ethylenediaminedipropionic acid and N,N′-Ethylenediaminetetrapropionic acid. J Am Chem Soc, 75: 4814–4818, 1953.
20.
Delmastro-GreenwoodMM, TseHM, and PiganelliJD. Effects of metalloporphyrins on reducing inflammation and autoimmunity. Antioxid Redox Signal, 20: 2465–2477, 2014.
21.
Delmastro-GreenwoodMM, VotyakovaT, GoetzmanE, MarreML, PreviteDM, TovmasyanA, Batinic-HaberleI, TruccoMM, and PiganelliJD. Mn porphyrin regulation of aerobic glycolysis: implications on the activation of diabetogenic immune cells. Antioxid Redox Signal, 19: 1902–1915, 2013.
22.
DoraiT, FishmanAI, DingC, Batinic-HaberleI, GoldfarbDS, and GrassoM. Amelioration of renal ischemia-reperfusion injury with a novel protective cocktail. J Urol, 186: 2448–2454, 2011.
23.
EckshtainM, ZilbermannI, MahammedA, SaltsmanI, OkunZ, MaimonE, CohenH, MeyersteinD, and GrossZ. Superoxide dismutase activity of corrole metal complexes. Dalton Trans, 14: 7879–7882, 2009.
24.
FaulknerKM, LiochevSI, and FridovichI. Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J Biol Chem, 269: 23471–23476, 1994.
25.
FormanHJ, DaviesKJ, and UrsiniF. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med, 66: 24–35, 2014.
26.
GadSC, SullivanDWJr, CrapoJD, and SpainhourCB. A nonclinical safety assessment of MnTE-2-PyP, a manganese porphyrin. Int J Toxicol, 32: 274–287, 2013.
27.
GreenwaldMB, AnziS, Ben SassonS, Bianco-PeledH, and KohenR. Can nitroxides evoke the Keap1-Nrf2-ARE pathway in skin?. Free Radic Biol Med, 77: 258–269, 2014.
28.
HaberA and GrossZ. Catalytic antioxidant therapy by metallodrugs: lessons from metallocorroles. Chem Commun (Camb), 51: 5812–5827, 2015.
29.
HalliwellB. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch Biochem Biophys, 476: 107–112, 2008.
HempelN, CarricoPM, and MelendezJA. Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis. Anticancer Agents Med Chem, 11: 191–201, 2011.
32.
HempelN, YeH, AbessiB, MianB, and MelendezJA. Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic Biol Med, 46: 42–50, 2009.
33.
HolleyAK, MiaoL, St ClairDK, and St ClairWH. Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases. Antioxid Redox Signal, 20: 1567–1589, 2014.
34.
HolleyAK, XuY, NoelT, BakthavatchaluV, Batinic-HaberleI, and St ClairDK. Manganese superoxide dismutase-mediated inside-out signaling in HaCaT human keratinocytes and SKH-1 mouse skin. Antioxid Redox Signal, 20: 2347–2360, 2014.
35.
JaramilloMC, BriehlMM, Batinic-HaberleI, and TomeME. Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med, 83: 89–100, 2015.
36.
Jumbo-LucioniPP, RyanEL, HopsonML, BishopHM, WeitnerT, TovmasyanA, SpasojevicI, Batinic-HaberleI, LiangY, JonesDP, and Fridovich-KeilJL. Manganese-based superoxide dismutase mimics modify both acute and long-term outcome severity in a drosophila melanogaster model of classic galactosemia. Antioxid Redox Signal, 20: 2361–2371, 2014.
37.
KanamoriA, CatrinescuMM, MahammedA, GrossZ, and LevinLA. Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy. J Neurochem, 114: 488–498, 2010.
38.
KosI, BenovL, SpasojevicI, ReboucasJS, and Batinic-HaberleI. High lipophilicity of meta Mn(III) N-alkylpyridylporphyrin-based superoxide dismutase mimics compensates for their lower antioxidant potency and makes them as effective as ortho analogues in protecting superoxide dismutase-deficient Escherichia coli. J Med Chem, 52: 7868–7872, 2009.
39.
KupershmidtL, OkunZ, AmitT, MandelS, SaltsmanI, MahammedA, Bar-AmO, GrossZ, and YoudimMB. Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem, 113: 363–373, 2010.
40.
LeeJH, LeeYM, and ParkJW. Regulation of ionizing radiation-induced apoptosis by a manganese porphyrin complex. Biochem Biophys Res Commun, 334: 298–305, 2005.
41.
MarozA, KelsoGF, SmithRA, WareDC, and AndersonRF. Pulse radiolysis investigation on the mechanism of the catalytic action of Mn(II)-pentaazamacrocycle compounds as superoxide dismutase mimetics. J Phys Chem A, 112: 4929–4935, 2008.
42.
This reference has been deleted.
43.
MiarA, HeviaD, Munoz-CimadevillaH, AstudilloA, VelascoJ, SainzRM, and MayoJC. Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. Free Radic Biol Med, 85: 45–55, 2015.
44.
MiriyalaS, SpasojevicI, TovmasyanA, SalveminiD, VujaskovicZ, St ClairD, and Batinic-HaberleI. Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta, 1822: 794–814, 2012.
45.
MiriyalaS, ThippakornC, ChaiswingL, XuY, NoelT, TovmasyanA, Batinic-HaberleI, Vander KooiCW, ChiW, LatifAA, PanchatcharamM, PrachayasittikulV, Allan ButterfieldD, VoreM, MoscowJ, andSt ClairDK.Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling. Free Radic Biol Med, 91: 68–80, 2016.
46.
OkunZ and GrossZ. Fine tuning the reactivity of corrole-based catalytic antioxidants. Inorg Chem, 51: 8083–8090, 2012.
PanH, ShenK, WangX, MengH, WangC, and JinB. Protective effect of metalloporphyrins against cisplatin-induced kidney injury in mice. PLoS One, 9: e86057, 2014.
49.
PasternackRF and HalliwellB. Superoxide dismutase activities of an iron porphyrin and other iron complexes. J Am Chem Soc, 101: 1026–1031, 1979.
50.
PrasannaPG, NarayananD, HallettK, BernhardEJ, AhmedMM, EvansG, VikramB, WeingartenM, and ColemanCN. Radioprotectors and radiomitigators for improving radiation therapy: the small business innovation research (SBIR) gateway for accelerating clinical translation. Radiat Res, 184: 235–248, 2015.
51.
RajicZ, TovmasyanA, SpasojevicI, ShengH, LuM, LiAM, GrallaEB, WarnerDS, BenovL, and Batinic-HaberleI. A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity. Free Radic Biol Med, 52: 1828–1834, 2012.
52.
RawalM, SchroederSR, WagnerBA, CushingCM, WelshJL, ButtonAM, DuJ, SibenallerZA, BuettnerGR, and CullenJJ. Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generation. Cancer Res, 73: 5232–5241, 2013.
53.
ReboucasJS, SpasojevicI, and Batinic-HaberleI. Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure-activity relationship as a watchdog mechanism in experimental therapeutics and biology. J Biol Inorg Chem, 13: 289–302, 2008.
54.
ReboucasJS, SpasojevicI, and Batinic-HaberleI. Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes. J Pharm Biomed Anal, 48: 1046–1049, 2008.
55.
RileyDP, LennonPJ, NeumannWL, and WeissRH. Toward the rational design of superoxide dismutase mimics: mechanistic studies for the elucidation of substituent effects on the catalytic activity of macrocyclic manganese(II) complexes. J Am Chem Soc, 119: 6522–6528, 1997.
56.
RosenthalRA, FishB, HillRP, HuffmanKD, LazarovaZ, MahmoodJ, MedhoraM, MolthenR, MoulderJE, SonisST, TofilonPJ, and DoctrowSR. Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem, 11: 359–372, 2011.
57.
SalveminiD, WangZQ, ZweierJL, SamouilovA, MacarthurH, MiskoTP, CurrieMG, CuzzocreaS, SikorskiJA, and RileyDP. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science, 286: 304–306, 1999.
58.
SchmidtHHHW, StockerR, VollbrachtC, PaulsenG, RileyD, DaiberA, and CuadradoA. Antioxidants in translational medicine. Antioxid Redox Signal, 23: 1130–1143, 2015.
59.
ShengH, ChaparroRE, SasakiT, IzutsuM, PearlsteinRD, TovmasyanA, and WarnerDS. Metalloporphyrins as therapeutic catalytic oxidoreductants in central nervous system disorders. Antioxid Redox Signal, 20: 2437–2464, 2014.
60.
SloskyLM and VanderahTW. Therapeutic potential of peroxynitrite decomposition catalysts: a patent review. Expert Opin Ther Pat, 25: 443–466, 2015.
61.
SmithRA and MurphyMP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci, 1201: 96–103, 2010.
62.
SpasojevićI and Batinić-HaberleI. Manganese(III) complexes with porphyrins and related compounds as catalytic scavengers of superoxide. Inorganica Chimica Acta, 317: 230–242, 2001.
63.
SpasojevicI, Batinic-HaberleI, StevensRD, HambrightP, ThorpeAN, GrodkowskiJ, NetaP, and FridovichI. Manganese(III) biliverdin IX dimethyl ester: a powerful catalytic scavenger of superoxide employing the Mn(III)/Mn(IV) redox couple. Inorg Chem, 40: 726–739, 2001.
64.
TovmasyanA, CarballalS, GhazaryanR, MelikyanL, WeitnerT, MaiaCG, ReboucasJS, RadiR, SpasojevicI, BenovL, and Batinic-HaberleI. Rational design of superoxide dismutase (SOD) mimics: the evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents. Inorg Chem, 53: 11467–11483, 2014.
65.
TovmasyanA, MaiaCG, WeitnerT, CarballalS, SampaioRS, LiebD, GhazaryanR, Ivanovic-BurmazovicI, Ferrer-SuetaG, RadiR, ReboucasJS, SpasojevicI, BenovL, and Batinic-HaberleI. A comprehensive evaluation of catalase-like activity of different classes of redox-active therapeutics. Free Radic Biol Med, 86: 308–321, 2015.
66.
TovmasyanA, ReboucasJS, and BenovL. Simple biological systems for assessing the activity of superoxide dismutase mimics. Antioxid Redox Signal, 20: 2416–2436, 2014.
TovmasyanA, WeitnerT, ShengH, LuM, RajicZ, WarnerDS, SpasojevicI, ReboucasJS, BenovL, and Batinic-HaberleI. Differential coordination demands in Fe versus Mn water-soluble cationic metalloporphyrins translate into remarkably different aqueous redox chemistry and biology. Inorg Chem, 52: 5677–5691, 2013.
69.
TownerRA and FloydRA. Nitrones as potent anticancer therapeutics. In: Redox-Active Therapeutics, edited by: Batinic-HaberleI, ReboucasJS, and SpasojevicI. Switzerland: Springer International Publishing, 2016.
70.
VukelicI, CelicT, RubinicN, SpanjolJ, BobinacM, TovmasyanA, Oberley-DeeganR, Batinic-HaberleI, and BobinacD. Understanding redox biology behind the therapeutic effects of redox active Mn porphyrins in spinal cord ischemia/reperfusion injury. Free Radic Biol Med, 87: S97–S98, 2015.
71.
WeitnerT, ShengH, MiriyalaS, LeuD, TovmasyanA, KosI, ReboucasJS, FanP, VujaskovicZ, Batinic-HaberleI, HuangTT, ClairDK, WarnerDS, and SpasojevicI. Comprehensive pharmocokinetic studies and biodistribution of two cationic Mn porphyrins-based catalysts, MnTE-2-PyP5+ and MnTnHex-2-PyP5+: plasma and organ oral availability, mitochondrial, cytosolic, whole brain, hippocampus and cortex distribution. Free Radic Biol Med, 53: S118, 2012.
72.
WeitzelDH, TovmasyanA, AshcraftKA, RajicZ, WeitnerT, LiuC, LiW, BuckleyAF, PrasadMR, YoungKH, RodriguizRM, WetselWC, PetersKB, SpasojevicI, Herndon JE 2nd, Batinic-HaberleI, and DewhirstMW. Radioprotection of the brain white matter by Mn(III) N-butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+. Mol Cancer Ther, 14: 70–79, 2015.